Phase I Study on the Effects of Vamorolone on Midazolam Pharmacokinetics in Healthy Male Volunteers for Duchenne and Becker Muscular Dystrophy

The primary objective of this study is to evaluate the effect of **vamorolone** on the induction of **CYP3A4** enzyme activity, as measured by the pharmacokinetics of **midazolam**, a sensitive CYP3A4 substrate. This is clinically relevant as it provides insights into potential drug-drug interactions and the metabolic profile of vamorolone, which is intended for use in conditions such as Duchenne muscular dystrophy and Becker muscular dystrophy. Understanding these interactions is crucial for optimizing therapeutic strategies and ensuring patient safety in these populations.

The clinical trial involves a **Phase I study** focusing on healthy male volunteers, with the intended indication for Duchenne muscular dystrophy and Becker muscular dystrophy. The study population includes both male and female participants, with an age range category code of 3, which typically corresponds to adults. The trial population was selected to include healthy individuals, although specific details regarding the selection process or lifestyle considerations such as diet or physical activity are not provided. The sponsor has not disclosed the total number of participants involved in the study. The trial also involves a vulnerable population, although further specifics on this aspect are not available. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed as a **Phase I study** involving healthy male volunteers, with the intended indication for **Duchenne muscular dystrophy** and **Becker muscular dystrophy**. The trial aims to evaluate the effect of vamorolone on the pharmacokinetics of midazolam, a sensitive CYP3A4 substrate. The study is structured as a randomized, double-blind, controlled trial to ensure the reliability and validity of the results. The estimated recruitment start date is August 20, 2024, with the trial expected to conclude by October 7, 2024, indicating a total duration of approximately two months.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following the screening, participants will be randomized into different study arms and will attend regular follow-up visits to monitor their response to the intervention and to collect pharmacokinetic data. These visits are crucial for assessing the primary and secondary endpoints of the trial. The study will culminate in an end-of-study visit, where final assessments will be conducted to gather conclusive data on the trial's objectives.

The expected length of participant involvement is aligned with the overall trial duration, spanning from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with study protocols, or withdraw consent. Such conditions are in place to ensure participant safety and the integrity of the trial data. The trial's design and procedures are meticulously planned to adhere to ethical standards and regulatory requirements, ensuring the collection of high-quality data to inform future research and potential therapeutic applications for the targeted muscular dystrophies.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 20, 2024, with an estimated completion date of October 7, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent with clinical standards. The trial's design and execution will adhere to the regulatory requirements for Phase 3 studies, focusing on the evaluation of treatment effects in a controlled environment.